{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:27:28Z","timestamp":1770269248023,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2000,9,1]],"date-time":"2000-09-01T00:00:00Z","timestamp":967766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2000,9]]},"DOI":"10.1007\/bf02725338","type":"journal-article","created":{"date-parts":[[2014,4,7]],"date-time":"2014-04-07T00:21:24Z","timestamp":1396830084000},"page":"588-592","source":"Crossref","is-referenced-by-count":91,"title":["A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the baylor experience)"],"prefix":"10.1007","volume":"7","author":[{"given":"Jeffery P.","family":"Lamont","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Nemunaitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Landers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd M.","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02725338_CR1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/(SICI)1097-0347(200001)22:1<34::AID-HED6>3.0.CO;2-3","volume":"22","author":"GJ Schwartz","year":"2000","unstructured":"Schwartz GJ, Mehta RH, Wenig BL, et al. Salvage treatment for recurrent squamous cell carcinoma of the oral cavity.Head Neck 2000;22:34\u201341.","journal-title":"Head Neck"},{"key":"BF02725338_CR2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archsurg.1979.01370250041008","volume":"114","author":"NW Pearlman","year":"1979","unstructured":"Pearlman NW. Treatment outcome in recurrent head and neck cancer.Arch Surg 1979;114:39\u201342.","journal-title":"Arch Surg"},{"key":"BF02725338_CR3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/archotol.1992.01880050029006","volume":"118","author":"KR Jones","year":"1992","unstructured":"Jones KR, Lodge-Rigal RD, Reddick RL, et al. Prognostic factors in the recurrence of stage I and II squamous cell cancer of the oral cavity.Arch Otolaryngol Head Neck Surg 1992;118:483\u20135.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"BF02725338_CR4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/0360-3016(76)90106-1","volume":"1","author":"KK Fu","year":"1976","unstructured":"Fu KK, Lichter A, Galante M. Carcinoma of the floor of the mouth: an analysis of treatment results and the sites and causes of failures.Int J Radiat Oncol Biol Phys 1976;1:829\u201337.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BF02725338_CR5","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1988.6.6.955","volume":"6","author":"J Paredes","year":"1988","unstructured":"Paredes J, Hong W, Felder T, et al. Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocaramate in recurrent and\/or metastatic squamous cell cancer of the head and neck.J Clin Oncol 1988;6:955\u201362.","journal-title":"J Clin Oncol"},{"key":"BF02725338_CR6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1992.10.2.257","volume":"10","author":"C Jacobs","year":"1992","unstructured":"Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.J Clin Oncol 1992;10:257\u201363.","journal-title":"J Clin Oncol"},{"key":"BF02725338_CR7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1992.10.8.1245","volume":"10","author":"A Forastiere","year":"1992","unstructured":"Forastiere A, Metch B, Schuller D, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: a southwest oncology group study.J Clin Oncol 1992;10:1245\u201351.","journal-title":"J Clin Oncol"},{"key":"BF02725338_CR8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1200\/JCO.1998.16.3.1054","volume":"16","author":"D Schrijvers","year":"1998","unstructured":"Schrijvers D, Johnson J, Jimenez U, et al. Phase III trial of modulation of cisplatin\/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer.J Clin Oncol 1998;16:1054\u20139.","journal-title":"J Clin Oncol"},{"key":"BF02725338_CR9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/bjc.1990.59","volume":"61","author":"Liverpool Head and Neck Oncology Group","year":"1990","unstructured":"Liverpool Head and Neck Oncology Group. A phase III randomized trial of cisplatin, methotrexate, cisplatin + methotrexate, and cisplatin + 5-FU in end stage squamous carcinoma of the head and neck.Br J Cancer 1990;61:311\u20135.","journal-title":"Br J Cancer"},{"key":"BF02725338_CR10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/oxfordjournals.annonc.a058906","volume":"5","author":"M Clavel","year":"1994","unstructured":"Clavel M, Vermorken J, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin, and vincristine (CABO) versus cisplatin and 5-fluorouracil versus cisplatin, in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC head and neck cancer cooperative group.Ann Oncol 1994;5:521\u20136.","journal-title":"Ann Oncol"},{"key":"BF02725338_CR11","first-page":"4477","volume":"53","author":"JO Boyle","year":"1993","unstructured":"Boyle JO, Hakim J, Kock WM, et al. The incidence of p53 mutations increases with progression of head and neck cancer.Cancer Res 1993;53:4477\u201380.","journal-title":"Cancer Res"},{"key":"BF02725338_CR12","first-page":"1131","volume":"142","author":"J Caamano","year":"1993","unstructured":"Caamano J, Zhang SY, Rosvold EA, et al. P53 alterations in human squamous cell carcinomas and carcinoma cell lines.Am J Pathol 1993;142:1131\u20139.","journal-title":"Am J Pathol"},{"key":"BF02725338_CR13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/jnci\/88.8.519","volume":"8","author":"DM Shin","year":"1996","unstructured":"Shin DM, Lee JS, Lippman SM, et al. p53 expression: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma.J Natl Cancer Inst 1996;8:519\u201328.","journal-title":"J Natl Cancer Inst"},{"key":"BF02725338_CR14","first-page":"1407","volume":"1","author":"ER Sauter","year":"1995","unstructured":"Sauter ER, Ridge JA, Litwin S, et al. Pretreatment p53 protein expression correlates with decreased survival in patients with end-stage head and neck cancer.Clin Cancer Res 1995;1:1407\u201312.","journal-title":"Clin Cancer Res"},{"key":"BF02725338_CR15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1101\/gad.7.4.546","volume":"7","author":"M Debbas","year":"1993","unstructured":"Debbas M, White E. Wild type p53 mediates apoptosis by E1A, which is inhibited by E1B.Genes Dev 1993;7:547\u201354.","journal-title":"Genes Dev"},{"key":"BF02725338_CR16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1006\/viro.1994.1480","volume":"203","author":"RJ Grand","year":"1994","unstructured":"Grand RJ, Grant ML, Gallimore PH. Enhanced expression of p53 in human cells infected with metastatic adenoviruses.Virology 1994;203:229\u201340.","journal-title":"Virology"},{"key":"BF02725338_CR17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1101\/gad.7.4.535","volume":"7","author":"SW Lowe","year":"1993","unstructured":"Lowe SW, Ruley HE. Stabilization of the p53 tumor suppression is induced by adenovirus 5E1A and accompanies apoptosis.Genes Dev 1993;7:535\u201340.","journal-title":"Genes Dev"},{"key":"BF02725338_CR18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.cgt.7700071","volume":"6","author":"CC Heise","year":"1999","unstructured":"Heise CC, Williams A, Olesch J, et al. Efficacy of a replication competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distant effects.Cancer Gen Ther 1999;6:499\u2013504.","journal-title":"Cancer Gen Ther"},{"key":"BF02725338_CR19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nm0697-639","volume":"6","author":"CC Heise","year":"1997","unstructured":"Heise CC, Sampson-Johannes A, Williams A, et al. ONYX-015, and E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.Nat Med 1997;6:639\u201345.","journal-title":"Nat Med"},{"key":"BF02725338_CR20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","volume":"274","author":"JR Bischoff","year":"1996","unstructured":"Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.Science 1996;274:373\u20136.","journal-title":"Science"},{"key":"BF02725338_CR21","unstructured":"Khuri F, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-FU in patients with recurrent head and neck cancer.Nat Med (in press)."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02725338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02725338\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02725338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T08:40:47Z","timestamp":1565340047000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02725338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["BF02725338"],"URL":"https:\/\/doi.org\/10.1007\/bf02725338","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,9]]}}}